Abstract
Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Role of Epigenetics and Oxidative Stress in Gliomagenesis
Volume: 16 Issue: 10
Author(s): Yesennia Sanchez-Perez, Ernesto Soto-Reyes, Claudia M. Garcia-Cuellar, Bernardo Cacho-Diaz, Abel Santamaria and Edgar Rangel-Lopez*
Affiliation:
- National Institute of Neurology and Neurosurgery, Laboratory of Excitatory Amino Acids. Av. Insurgentes Sur #3877 Col. La Fama. Delegacion Tlalpan, C.P. 14269 Mexico City,United States
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Abstract: Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Export Options
About this article
Cite this article as:
Sanchez-Perez Yesennia, Soto-Reyes Ernesto , Garcia-Cuellar M. Claudia, Cacho-Diaz Bernardo , Santamaria Abel and Rangel-Lopez Edgar *, Role of Epigenetics and Oxidative Stress in Gliomagenesis, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527317666180110124645
DOI https://dx.doi.org/10.2174/1871527317666180110124645 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Influence of Polymer Molecular Weight on in-vitro Characteristics and Cytotoxicity of Fulvestrant Loaded Nanoparticles
Current Drug Therapy Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Editorial [Hot Topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Challenges and Opportunities in Molecular Imaging
Current Medical Imaging Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB
Anti-Cancer Agents in Medicinal Chemistry Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Nanomedical Platform for Drug Delivery in Cancer
Current Organic Chemistry Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology Combination Treatment of Glioblastoma by Low-Dose Radiation and Genistein
Current Radiopharmaceuticals Recent Patents on the Development of c-Met Kinase Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry A Simple, Efficient and Environmentally Benign Synthetic Protocol for the Synthesis of Spirooxindoles Using Choline Chloride-Oxalic Acid Eutectic Mixture as Catalyst/Solvent System
Combinatorial Chemistry & High Throughput Screening Systemic Therapeutic Gene Delivery for Cancer: Crafting Paris Arrow
Current Gene Therapy Aggrecanase: The Family and Its Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Integrins in Bone Metastasis Formation and Potential Therapeutic Implications
Current Cancer Drug Targets